689 research outputs found
Judge Norris S. Barratt papers
No full textThe Papers of Judge Norris S. Barratt, a Philadelphia lawyer and author of Barratt's Chapel and Methodism, consist of fourteen letters he received from James H. Preston sent during Preston's first term as mayor of Baltimore, Maryland, (1911-1915) and three of Barratt's letters sent to Preston. The letters are both political and personal in nature. Also included are an invitation to a Symbolic Silver Service for James Cardinal Gibbons, Archbishop of Baltimore, at Baltimore's City Hall and two pamphlets on Baltimore and Mayor Preston
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study
No full textAbstract not availableDaniel T. Barratt, Benedikte Bandak, Pål Klepstad, Ola Dale, Stein Kaasa, Lona L. Christrup, Jonathan Tuke, Andrew A. Somogy
Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
No full textIntroduction: This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. Methods: Efficacy and safety results from four phase 3, randomized, open-label studies comparing roxadustat to ESAs (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES) in dialysis-dependent patients with anemia of chronic kidney disease (CKD) were evaluated by study, pooled population and in two subgroups: incident dialysis and stable dialysis. The primary efficacy endpoint per study was hemoglobin change from baseline (CFB) to weeks 28-36 using least-squares mean difference (LSMD) without rescue therapy. Pooled safety endpoints included time to major adverse cardiovascular event (MACE; myocardial infarction, stroke, and all-cause mortality [ACM]) and MACE+ (MACE plus congestive heart failure or unstable angina requiring hospitalization), ACM, and treatment-emergent adverse events (TEAEs). MACE and MACE+ were evaluated for non-inferiority at 1.8 and 1.3 margins using hazard ratios (HRs) and 95% confidence intervals (CIs). TEAEs were descriptively summarized. Results: In total, 4714 patients were randomized (2354 roxadustat; 2360 ESA). Hemoglobin CFB to weeks 28-36 achieved non-inferiority for roxadustat vs ESA in each study. Roxadustat was non-inferior to ESA for risks for MACE and MACE+ in the entire cohort (MACE: HR 1.09, 95% CI 0.95-1.26; MACE+ : HR 0.98, 95% CI 0.86-1.11) and similar to the incident dialysis and stable dialysis subgroups; ACM results were consistent with MACE and MACE+ (HR 1.13, 95% CI 0.95-1.34). TEAEs were generally comparable between groups. Conclusion: Roxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients
Modelling individual preferences for environmental policy drivers: Empirical evidence of Italian lifestyle changes using a latent class approach
No full textDegraded air quality severely affects the health of citizens worldwide. The design of effective policies requires exploring public preferences for environmental and air quality policy instruments. Within the EC-FP7 SEFIRA project, using a choice experiment that stresses the trade-offs between attributes, this study investigates public preferences for environmental policy drivers in Italy. The main objective is to investigate the role played by selected policy drivers in determining policy preferences, complemented by elasticity and willingness to pay estimations. Preference heterogeneity and the role of socio-economic and attitudinal variables are explored with a latent class model over 2400 respondents sampled across Italy. The results allow identifying the different role played by the policy drivers across the classes. It emerged that most of the respondents (43%) are particularly sensitive to the cost components (cost sensitive respondents). The remaining respondents instead show an important sensitivity towards personal engagement in term of changes in the mobility and eating habits (lifestyle-change sensitive respondents). However, while 29% of them perceive these habits’ changes as negatively impacting on the personal utility, the other 28% of respondents translate the potential changes in the habitual behaviour of driving and eating as environmental and health benefits. Based on the modelling results, potential policies are simulated reporting respondents’ reaction to selected scenarios. It shows the crucial role played by reduction of premature deaths due to atmospheric pollution and measure cost.
ã 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-N
Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy
No full textJonathan Barratt,1 Jens Kristensen,2 Christian Pedersen,2 Markus Jerling3 1College of Life Sciences, University of Leicester, Leicester, UK; 2Calliditas Therapeutics AB, Stockholm, Sweden; 3Markus Jerling Consulting AB, Stockholm, SwedenCorrespondence: Jonathan Barratt, College of Medicine, Biological Sciences and Psychology, University of Leicester, Leicester, UK, Tel +44 0116 258 8043, Email [email protected]: Immunoglobulin A nephropathy (IgAN) is a chronic, immune-mediated kidney disease characterized by the deposition of galactose-deficient immunoglobulin A1 (Gd-IgA1) in the kidneys. Excess Gd-IgA1 production in patients with IgAN is located within the mucosa-associated lymphoid tissue, particularly within the lamina propria in the distal ileum. Nefecon® is a targeted-release formulation of the corticosteroid budesonide, which became the first treatment approved by the US Food and Drug Administration (FDA; brand name, TARPEYO®) and European Medicines Agency (EMA; KINPEYGO®) for patients with primary IgAN at risk of rapid disease progression, after demonstrating clinically significant reduction of proteinuria in an interim analysis of the Phase III NefIgArd trial. After showing a significant reduction in estimated glomerular filtration rate decline in the full 2-year analysis of the trial, Nefecon was granted full approval by the FDA to reduce the loss of kidney function. Nefecon was specifically designed to deliver budesonide to the distal ileum, selectively targeting excess Gd-IgA1 production in the gut-associated lymphoid tissue. In this review, we describe the properties of Nefecon and the evidence to date that confirms its localized treatment effect. We also present unpublished evidence from Phase I trials investigating the pharmacokinetics and cortisol suppression effects of Nefecon in healthy participants. These studies demonstrated that Nefecon has a distinct pharmacokinetic profile from other budesonide products, allowing for targeted, localized action in the distal ileum. When considered alongside existing clinical trial data showing the effect of Nefecon on gut-associated biomarkers, available evidence indicates that Nefecon has a selective immunomodulatory mechanism of action and a direct disease-modifying effect in patients with IgAN, while having low systemic exposure and adverse effects.Keywords: drug delivery, biomarkers, pharmacokinetics, GAL
ASSISTED REPRODUCTIVE TECHNOLOGY: ACCOMPLISHMENTS AND NEW HORIZONS
No full textList of contributors -- Foreword -- Pt. I. The gametes: present and future -- Ch. 1. Spermatogenesis in vitro in mammals / Bernard Jegou, Charles Pineau, and Jorma Toppari -- Ch. 2. The spermatozoon as a machine: compartmentalized pathways bridge cellular structure and function / Alexander J. Travis and Gregory S. Kopf -- Ch. 3. Attributes of fertile spermatozoa / Christopher De Jonge and Christopher L.R. Barratt -- Ch. 4. In vitro oogenesis / Frank L. Barnes -- Ch. 5. The oocyte as a machine / Kate Hardy - - Ch. 6. Follicular influences on oocyte and embryo competence / Jonathan van Blerkom -- Ch. 7. Unresolved and basic problems in assisted reproductive technology / Jim Cummins -- Pt. II. Techniques: present and future -- Ch. 8. Influences of culture media on embryo development / Barry Bavister and Jay Baltz -- Ch. 9. Cryopreservation of immature and mature gametes / John K. Critser, Yuksel Agca, and Erik J. Woods -- Ch. 10. Embryonic stem cells / Ann M. Lawler and John D. Gearhart -- Ch. 11. Modification of the male genome by gene and spermatogonial transplantation / Peter J. Donovan, Michael D. Griswold, and Lonnie D. Russell -- Ch. 12. Genetic diagnosis: the future / David Cram and David de Kretser -- Ch. 13. Cloning mammals / Don P. Wolf and Shoukhrat Mitalipov - - Ch. 14. Fluorescence imaging: gamete selection and intracellular sperm injection / Laura Hewitson, Cal Simerly, and Gerald Schatten -- Pt. III. The clinic -- Ch. 15. Diagnosis and the treatment of male infertility / Axel Kamischke and Eberhard Nieschlag -- Ch. 16. Tests of male fertility / R. John Aitken -- Ch. 17. Diagnosis and treatment for female subfertility / Peter Platteau and Paul Devroey -- Ch. 18. Ultrasound imaging at the beginning of the second millennium / Richard P. Dickey and Ellen Matulich -- Ch. 19. The natural and the stimulated cycle / Ian D. Cooke -- Ch. 20. Embryo stage and transfer number / Alan Trounson -- Ch. 21. The federal research base in the USA for assisted reproductive technology / Donna L. Vogel -- Pt. IV. Concepts for the global community -- Ch. 22. From conception to contraception / Gustavo F. Doncel, Christine Mauck, Douglas S. Colvard, and Lourens J.D. Zaneveld -- Ch. 23. Developing immunocontraceptives / Eileen A. McLaughlin and Michael K. Holland -- Ch. 24. ARTistic licence: should assisted reproductive technologies be regulated? / Nanette R. Elster -- Ch. 25. Finances and access to assisted reproductive technologies: justice and publication of results / Francoise Shenfield -- Ch. 26. Sex selection / Joe Leigh Simpson and Sandra Ann Carson -- Ch. 27. Intracytoplasmic sperm injection: a time bomb? / Herman J. Tournaye and Andre C. Van Steirteghem -- Ch. 28. Cryopreservation of gametes and embryos: legal and ethical aspects / Susan M. Avery and Peter R. Brinsden -- Inde
Dynamically motivated spectroscopy of small polyatomic molecules
No full textThesis: Ph. D., Massachusetts Institute of Technology, Department of Chemistry, 2015.This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.Cataloged from student-submitted PDF version of thesis.Includes bibliographical references (pages 246-262).Molecular vibrational dynamics far from equilibrium, or in the vicinity of saddle points, are of utmost importance in chemistry. However, most of the standard models used by chemists only perform well near local minima in the potential energy surface. Several spectroscopic techniques are developed and applied to the study of molecules in excited states, including chirped-pulse millimeter wave spectroscopy and adaptations of millimeter-wave optical double resonance. Models for Franck-Condon factors in the linear-to-bent S₁-S₀ transition of acetylene elucidate the dynamics of bright states observed in the fluorescence spectrum and provide insight for the design of spectroscopic schemes for accessing barrier-proximal vibrational levels. IR-UV double resonance spectroscopy enables characterization of the source of staggering in the antisymmetric stretch progression of the C̃ state of SO₂, which arises due to vibronic interactions that lead to non-equivalent equilibrium SO bond lengths.by G. Barratt Park.Ph. D
- …
